Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) – Pipeline Review, H1 2018’, provides in depth analysis on Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Immunology, Cardiovascular, Gastrointestinal, Genito Urinary System And Sex Hormones, Hematological Disorders, Infectious Disease, Metabolic Disorders, Ophthalmology and Toxicology under development targeting Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

– The report provides a snapshot of the global therapeutic landscape for Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62)

– The report reviews Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) targeted therapeutics and enlists all their major and minor projects

– The report assesses Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Bellicum Pharmaceuticals Inc

BeyondSpring Pharmaceuticals Inc

Novartis AG

Pharmedartis GmbH

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC

3.4.22.62) Overview

Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC

3.4.22.62) Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC

3.4.22.62) Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC

3.4.22.62) Companies Involved in Therapeutics Development

Bellicum Pharmaceuticals Inc

BeyondSpring Pharmaceuticals Inc

Novartis AG

Pharmedartis GmbH

Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC

3.4.22.62) Drug Profiles

emricasan Drug Profile

Product Description

Mechanism Of Action

R&D Progress

flavokawain A Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Protein to Activate CASP3 and CASP9 for Oncology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MBRI-001 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

plinabulin Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Activate Caspases for Diabetic Retinopathy, Age Related Macular Degeneration and Solid Tumor Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rimiducid + rivogenlecleucel Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate Caspase 8, 9 for Oncology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC

3.4.22.62) Dormant Products

Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC

3.4.22.62) Discontinued Products

Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC

3.4.22.62) Product Development Milestones

Featured News & Press Releases

Feb 05, 2018: BeyondSpring Summarizes Key Messages from KOL Call regarding Lead Asset Plinabulin for the Prevention of Docetaxel Chemotherapy-Induced Neutropenia

Jan 30, 2018: Bellicum Pharmaceuticals Announces Clinical Hold on BPX-501 Clinical Trials in the United States

Jan 26, 2018: BeyondSpring Presents Promising Data for Lead Asset Plinabulin at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium

Jan 17, 2018: BeyondSpring to Present Data from Phase 2 Portion of Study 105 Phase 2/3 Trial with Plinabulin for the Prevention of Docetaxel Chemotherapy-Induced Neutropenia at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium

Dec 14, 2017: BeyondSpring Meets Primary Objective in Phase 2 Portion of Phase 2/3 Trial (Study 105) with Plinabulin for the Prevention of Docetaxel Chemotherapy-Induced Neutropenia

Dec 07, 2017: BeyondSpring to Webcast Key Opinion Leader Event in NYC on Dec. 14, 2017

Dec 04, 2017: BeyondSpring’s Lead Asset, Plinabulin, Recognized as 2017 National Science and Technology Major Project in China

Nov 30, 2017: BeyondSpring Initiates Global Phase 2/3 Trial with Plinabulin in China for the Prevention of Chemotherapy-Induced Neutropenia to Demonstrate Superiority

Oct 26, 2017: BeyondSpring Announces the First Patient Enrolled in China in its Global Phase 2/3 Trial with Plinabulin for the Prevention of Chemotherapy-Induced Neutropenia

Oct 23, 2017: BeyondSpring Receives Two Grants in China to Further Develop Innovative Drug Pipeline

Oct 18, 2017: BeyondSpring Chief Medical Officer to Present at the 2017 BIO Investor Forum on Oct. 18 in San Francisco

Aug 14, 2017: Conatus Announces Completion of Enrollment in ENCORE-NF Phase 2b Clinical Trial of Emricasan in Patients with NASH Fibrosis

Jul 06, 2017: China FDA Approves CTAs for BeyondSpring’s Second Global Plinabulin Registrational Trial for Chemotherapy-Induced Neutropenia Prevention

Jun 16, 2017: Conatus Pharmaceuticals Announces Poster Presentation at International Liver Cell Conference

Jun 15, 2017: BeyondSpring Chief Medical Officer to Present Clinical Data for Lead Asset Plinabulin at 2017 BIO International Convention in San Diego

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indications, H1 2018

Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Bellicum Pharmaceuticals Inc, H1 2018

Pipeline by BeyondSpring Pharmaceuticals Inc, H1 2018

Pipeline by Novartis AG, H1 2018

Pipeline by Pharmedartis GmbH, H1 2018

Dormant Products, H1 2018

Dormant Products, H1 2018 (Contd..1), H1 2018

Discontinued Products, H1 2018

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports